Exploring an herbal “wonder cure” for cancer: a multidisciplinary approach
- 576 Downloads
Context and objectives
The unmonitored use of herbal medicinal remedies by patients with cancer presents a significant challenge to oncology healthcare professionals. We describe an increasingly popular herbal “wonder drug,” Ephedra foeminea (Alanda in Arabic), whose use has spread from the Palestinian patient population throughout the Middle East. We conducted a multicentered and multidisciplinary collaborative research effort in order to understand the potential benefits and harms of this popular herbal remedy.
We conducted an in-depth search of the medical literature, both traditional and modern, for any mention of the clinical use of Alanda for the treatment of cancer. We then tested the remedy, first for toxic ephedra alkaloid components and then for anticancer effects, as well as effects on the cytotoxic activity of chemotherapy agents (cisplatin and carboplatin) on breast cancer cell cultures.
We found no mention in the literature, both conventional and traditional, on the use of Alanda for the treatment of cancer. Laboratory testing did not find any toxic components (i.e., ephedra alkaloids) in the preparation. However, in vitro exposure to Alanda led to a reduced cytotoxic effect of chemotherapy on breast cancer cell cultures.
The use of an integrative ethnobotanical, laboratory and clinical research-based approach can be extremely helpful when providing nonjudgmental and evidence-based guidance to patients with cancer, especially on the use of traditional herbal medicine. The effectiveness and safety of these products need to be examined by integrative physicians who are dually trained in both complementary medicine and supportive cancer care.
KeywordsIntegrative medicine Herbal medicine Complementary medicine Quality-of-life (QOL) Drug–herb interactions Ephedra foeminea
We thank Abu-Sabri Saleh Said Khair, traditional herbal practitioner, Peqi'in, Israel; Ehud (Udi Wolf), PhD, the director of the Analytic Laboratory, Division of Identification & Forensic Sciences, Israel Police, Jerusalem, Israel; Michal Rotenberg, PhD, the head of the Clinical Toxicology and Pharmacology Laboratory, Sheba Medical Center, Tel Hashomer, Israel; Nihaya M.Y. Salameh, MSc, Researcher, Biodiversity & Environmental Research Center, BERC, Til, Nablus, Palestine; and Farah Raslan, MSc, Cancer Drug Discovery Program, Galilee Technology Center, Kiryat Shmona, Israel.
All authors contributed equally to the design and drafting of the article.
Compliance with ethical standards
Conflict of interest
Prof. Eran Ben-Arye declares that he has no conflict of interest. Dr. Jamal Mahajna declares that he has no conflict of interest. Dr. Radi Aly declares that he has no conflict of interest. Dr. Mohammed Saleem Ali-Shtayeh declares that he has no conflict of interest. Prof. Yedidia Bentur declares that he has no conflict of interest. Prof. Efraim Lev declares that he has no conflict of interest. Dr. Gary Deng declares that he has no conflict of interest. Dr. Noah Samuels declares that he has no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- Ben-Arye E, Hamadeh AM, Schiff E, Jamous RM, Dagash J, Jamous RM, Agbarya A, Bar-Sela G, Massalha E, Silbermann M, Ali-Shtayeh MS (2015) Compared perspectives of Arab patients in Palestine and Israel on the role of complementary medicine in cancer care. J Pain Symptom Manag 49(5):878–884CrossRefGoogle Scholar
- Ben-Arye E, Samuels N, Goldstein LH, Mutafoglu K, Omran S, Schiff E, Charalambous H, Dweikat T, Ghrayeb I, Bar-Sela G, Turker I, Hassan A, Hassan E, Saad B, Nimri O, Kebudi R, Silbermann M (2016a) Potential risks associated with traditional herbal medicine use in cancer care: a study of Middle Eastern oncology health care professionals. Cancer 122(4):598–610CrossRefPubMedGoogle Scholar
- Ben-Arye E, Popper-Giveon A, Samuels N, Mutafoglu K, Schiff E, Omran S, Charalambous H, Dweikat T, Ghrayeb I, Turker I, Hassan A, Hassan E, Nimri O, Kebudi R, Silbermann M (2016b) Communication and integration: a qualitative analysis of perspectives among Middle Eastern oncology healthcare professionals on the integration of complementary medicine in supportive cancer care. J Cancer Res Clin Oncol. 1 Feb 2016 [Epub ahead of print]Google Scholar
- Cassileth BR, Yarett IR (2012) Cancer quackery: the persistent popularity of useless, irrational ‘alternative’ treatments. Oncology (Williston Park) 26(8):754–758Google Scholar
- https://www.youtube.com/watch?feature=player_embedded&v=_va60JRYQpc. Accessed 6 April 2016
- https://www.youtube.com/watch?v=UvnkGnSKF58. Accessed 6 April 2016
- https://www.youtube.com/watch?v=nlk9WycENVI. Accessed 6 April 2016
- http://www.fda.gov/Food/DietarySupplements/ProductsIngredients/default.htm. Accessed 14 April 2016
- Internet site: https://www.youtube.com/watch?v=-pvk49ar8PI. Accessed 6 April 2016
- Lev E (2002) Medicinal substances of the medieval Levant. Eretz Publications, Tel AvivGoogle Scholar
- Lev E, Amar Z (2008) Practical materia medica of the medieval Eastern Mediterranean according to the Cairo Genizah. Brill, LeidenGoogle Scholar
- Natural Medicines comprehensive database (2015) Internet site: http://www.mskcc.org/mskcc/html/11570.cfm. Accessed 2 Oct 2015
- Philips J (1958) Some Lebanese materia medica. Ph.D. Thesis published in Lebanese Folk Cure. Columbia University, pp 120–121Google Scholar
- Sloan-Kettering Herb Reference (2015) Internet site: http://www.mskcc.org/mskcc/html/11570.cfm. Accessed 16 Dec 2015
- Yin A, Lawrence DF, Constantin FA (2013) Identifying unproven cancer treatments on the health web: addressing accuracy, generalizability and scalability. Stud Health Technol Inf 192:667–671Google Scholar